Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 6, 2006, Pages 413-418

  Matias, I ^a   Wang, J W ^b   Moriello, A Schiano ^a   Nieves, A ^b   Woodward, D F ^b   Di Marzo, V ^a  

^a CNR   (Italy)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; PALMIDROL;

ARTICLE; AUTOPSY; CHOROID; CILIARY BODY; CONTROLLED STUDY; CORNEA; DIABETIC RETINOPATHY; HUMAN; HUMAN TISSUE; IRIS; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION;

ARACHIDONIC ACIDS; DIABETIC RETINOPATHY; ENDOCANNABINOIDS; EYE; GLYCERIDES; HUMANS; MACULAR DEGENERATION; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; UP-REGULATION;

EID: 33750452664     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.08.002     Document Type: Article

References (50)

1. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 377-391
2. Howlett A.C., Barth F., Bonner T.I., et al. International union of pharmacology, XXVII: classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
3. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141 (2004) 765-774
4. Sugiura T., and Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem. Phys. Lipids 108 (2000) 89-106
5. Devane W.A., Hanuš L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
6. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140 (2003) 790-801
7. Lambert D.M., Vandevoorde S., Jonsson K.O., and Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem. 9 (2002) 663-674
8. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr. Med. Chem. 6 (1999) 757-773
9. De Petrocellis L., Davis J.B., and Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506 (2001) 253-256
10. Lo Verme J., La Rana G., Russo R., Calignano A., and Pomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 77 (2005) 1685-1698
11. Järvinen T., Pate D.W., and Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. 95 (2002) 203-220
12. 1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur. J. Pharmacol. 431 (2001) 277-286
13. Chen J., Matias I., Dinh T., et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem. Biophys. Res. Commun. 30 (2005) 1062-1067
14. Porcella A., Casellas P., Gessa G.L., and Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res. Mol. Brain Res. 58 (1998) 240-245
15. Porcella A., Maxia C., Gessa G.L., and Pani L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur. J. Neurosci. 12 (2000) 1123-1127
16. Lu Q., Straiker A., Lu Q., and Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis. Neurosci. 17 (2000) 91-95
17. Yazulla S., Studholme K.M., McIntosh H.H., and Deutsch D.G. Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. J. Comp. Neurol. 415 (1999) 80-90
18. Yazulla S., and Studholme K.M. Vanilloid receptor like 1 (VRL1) immunoreactivity in mammalian retina: colocalization with somatostatin and purinergic P2×1 receptors. J. Comp. Neurol. 474 (2004) 407-418
19. Schlicker E., Timm J., and Göthert M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn Schmiedebergs Arch. Pharmacol. 354 (1996) 791-795
20. Yazulla S., Studholme K.M., McIntosh H.H., and Fan S.F. Cannabinoid receptors on goldfish retinal bipolar cells: electron-microscope immunocytochemistry and whole-cell recordings. Vis. Neurosci. 17 (2000) 391-401
21. Fan S.F., and Yazulla S. Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2. Vis. Neurosci. 20 (2003) 177-188
22. Straiker A., and Sullivan J.M. Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander. J. Neurophysiol. 89 (2003) 2647-2654
23. Pryce G., Ahmed Z., Hankey D.J.R., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003) 2191-2202
24. Pate D.W., Järvinen K., Urtti A., Mahadevan V., and Järvinen T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 63 (1998) 2181-2188
25. Porcella A., Maxia C., Gessa G.L., and Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13 (2001) 409-412
26. Chien F.Y., Wang R.F., Mittag T.W., and Podos S.M. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 121 (2003) 87-90
27. Laine K., Järvinen T., Savinainen J., Laitinen J.T., Pate D.W., and Järvinen K. Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. Pharm. Res. 18 (2001) 494-499
28. Laine K., Järvinen K., Mechoulam R., Breuer A., and Järvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3216-3222
29. Di Marzo V., and De Petrocellis L. Plant, synthetic and endogenous cannabinoids in medicine. Annu. Rev. Med. 57 (2006) 553-574
30. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
31. Hamdi H.K., and Kenny C. Age-related macular degeneration: a new view point. Frontiers Biosci. 8 (2003) 305-314
32. Gryziewicz L. Regulatory aspects of drug approval for macular degeneration. Adv. Drug Deliv. Rev. 57 (2005) 2092-2098
33. Zarbin M. Current concepts in the pathogenesis of ag-related macular degeneration. Arch. Ophthalmol. 122 (2004) 598-613
34. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., and Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol. Therap. 2 (2000) 601-608
35. El-Remessy A.B., Al-Shabrawey M., Khalifa Y., Tsai N.T., Caldwell R.B., and Liou G.I. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol. 168 (2006) 235-244
36. Haines J.L., Hauser M.A., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
37. Conley Y.P., Thalamuthu A., Jakobsdottir J., et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum. Mol. Genet. 14 (2005) 1991-2002
38. Funatsu H., and Yamashita H. Pathophysiology of diabetic retinopathy. Drug News Perspect. 15 (2002) 633-639
39. Sen K., Misra A., Kumar A., and Pandey R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56 (2002) 1-11
40. D. Panikashvili, N.A. Shein, R. Mechoulam, et al., The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. Dec 16 (2005) (Epub ahead of print).
41. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3 (2004) 771-784
42. Romero J., Lastres-Becker I., De Miguel R., Berrendero F., Ramos J.A., and Fernandez-Ruiz J. The endogenous cannabinoid system and the basal ganglia, biochemical, pharmacological, and therapeutic aspects. Pharmacol. Ther. 95 (2002) 137-152
43. De Petrocellis L., and Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci. 77 (2005) 1651-1666
44. Straiker A.J., Maguire G., Mackie K., and Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2442-2448
45. Straiker A., Stella N., Pomelli D., Mackie K., Karten H.J., and Maguire G. Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc. Natl. Acad. Sci. USA 96 (1999) 14565-14570
46. b receptor-dependent G protein activity in transducin-deactivated membranes and autoradiography sections of rat retina. Cell Mol. Neurobiol. 24 (2004) 243-256
47. Di Marzo V., Melck D., Orlando P., et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358 (2001) 249-255
48. Veldhuis W.B., van der Stelt M., Wadman M.W., et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23 (2003) 4127-4133
49. Pegorini S., Braida D., Verzoni C., et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br. J. Pharmacol. 144 (2005) 727-735
50. Nilsson S.F.E., Mäepea O., Alm A., and Narfström K. Ocular blood flow and retinal metabolism in Abyssinian cats with hereditary retinal degeneration. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1038-1044